BI
GYRE icon

BVF Inc’s Gyre Therapeutics GYRE Stock Holding History

BVF Inc’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-7,696
Closed -$1.05M – 30
2016
Q3 		$1.05M Sell
7,696
-935
-11% -$141K 0.2% 28
2016
Q2 		$1.48M Hold
8,631
– – 0.31% 30
2016
Q1 		$1.63M Hold
8,631
– – 0.4% 26
2015
Q4 		$3.04M Sell
8,631
-443
-5% -$174K 0.52% 24
2015
Q3 		$4.76M Buy
9,074
+623
+7% +$950K 0.96% 19
2015
Q2 		$18.6M Hold
8,451
– – 3.28% 13
2015
Q1 		$19.8M Hold
8,451
– – 4.13% 10
2014
Q4 		$17.5M Hold
8,451
– – 3.4% 11
2014
Q3 		$16.8M Hold
8,451
– – 3.5% 9
2014
Q2 		$30M Buy
8,451
+614
+8% +$2M 4.75% 7
2014
Q1 		$29.3M Hold
7,837
– – 4.54% 8
2013
Q4 		$25.6M Hold
7,837
– – 4.48% 7
2013
Q3 		$32.8M Hold
7,837
– – 5.64% 6
2013
Q2 		$26.4M Buy
+7,837
New +$29.8M 5.11% 7

Other funds holding GYRE

EWM
Essex Woodlands Management The Woodlands, Texas $254M AUM 4.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IP
Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return
CCM
Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

BVF Inc's GYRE Position: Q4 2016 in Review

BVF Inc sold out of Gyre Therapeutics (GYRE) in Q4 2016, closing a stake of 7,696 shares — an estimated $1.05M sold.

BVF Inc first reported a position in GYRE in Q2 2013 and held it in 14 quarters. The position peaked at $32.8M in Q3 2013. 27 funds tracked by Wall St. Rank hold GYRE as of Q4 2016.

  • BVF Inc reported no remaining Gyre Therapeutics position as of Q4 2016 after selling out during the quarter.
  • BVF Inc sold 7,696 Gyre Therapeutics shares in Q4 2016, an estimated $1.05M.
  • BVF Inc first reported a position in Gyre Therapeutics in Q2 2013 and held it in 14 quarters.
  • BVF Inc's Gyre Therapeutics position peaked at $32.8M in Q3 2013.
  • 27 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2016.

Based on BVF Inc's 13F filing for Q4 2016, filed 14 Feb 2017.